{"name":"Nuvectra Corporation","slug":"nuvectra","ticker":"NVTR","exchange":"NASDAQ (Delisted)","domain":"nuvectra.com","description":"Nuvectra Corporation is a medical technology company focused on neuromodulation therapies. The company's top products include the Algovita spinal cord stimulation system and the Vagus Nerve Stimulation Therapy System. Nuvectra's products are used to treat chronic pain and other conditions. The company is a leading player in the neuromodulation market.","hq":"Plano, TX","founded":0,"employees":"","ceo":"Scott Thorpe (former)","sector":"MedTech / Neuromodulation","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"Delisted","metrics":{"revenue":18000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Algovita patent cliff ($0.0B at risk)","drug":"Algovita","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Nuvectra Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Nuvectra reported revenue of $14.4 million for the fourth quarter of 2023, down 21% from the same period in 2022. The company also reported a net loss of $10.4 million for the quarter.","drugName":"","sentiment":"negative"},{"date":"2023-11-07","type":"deal","headline":"Nuvectra Announces Agreement to be Acquired by LivaNova","summary":"Nuvectra announced that it has entered into a definitive agreement to be acquired by LivaNova in an all-cash transaction valued at approximately $1.7 billion.","drugName":"","sentiment":"positive"},{"date":"2023-05-24","type":"regulatory","headline":"Algovita Spinal Cord Stimulation System Receives FDA Approval","summary":"The Algovita spinal cord stimulation system, developed by Nuvectra, has received FDA approval for the treatment of chronic pain.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNTW9iQVRaaVRXeEZ0YXF3clNXUjhSeXpsSDJBOW53QzhfbGRuVXZmdHdUWS1GMFU0SkM4UVlVM3pfYlNmbW1GdVF2WjBjUnMzcVV0aEZEcy11anc3d05MNGdoVzBoZUlXMmhTaEJ0VVdYWGFaRHEtU2dpSVU0M0Q4ZmRTdUxNbDNjS1RRYno0ZTJrb0d1bnZuZE50VFpmSENPTTYySXBEa3FRRXR5WUJkWHRvVQ?oc=5","date":"2018-05-03","type":"pipeline","source":"RTTNews","summary":"LENS Back In Focus, NVTR Rides High, BTAI For The Long Haul, CHRS Resubmits BLA - RTTNews","headline":"LENS Back In Focus, NVTR Rides High, BTAI For The Long Haul, CHRS Resubmits BLA","sentiment":"neutral"}],"patents":[{"drugName":"Algovita","drugSlug":"algovita","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Boston Scientific","Medtronic","LivaNova"],"therapeuticFocus":["Neuromodulation","Chronic Pain"],"financials":null,"yahoo":null}